Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
Open Posted
- Opportunity number
- PAR-25-282
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- Independent School Districts
- For Profit Organizations
- Other
- State Governments
- 501(c)(3) Nonprofits
- Special District Governments
- Non-501(c)(3) Nonprofits
- Higher Education Inst. (Private)
- Small Businesses
- Public or Indian Housing Auth.
- Tribal Organizations (Not Federally Recognized)
- County Governments
- City/Township Governments
- Tribal Governments (Federally Recognized)
- Higher Education Inst. (Public)
- Points of contact
-
- NIH OER Webmaster grantsinfo@nih.gov
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is soliciting applications for translational research on mood and psychosis symptoms during the menopause transition, with applications due January 7, 2028. This R21 mechanism supports innovative, hypothesis-driven research into the neurobiological and behavioral mechanisms underlying mood and psychotic disorders (including perimenopausal depression, generalized anxiety disorder, bipolar disorder, and schizophrenia) that emerge or worsen during menopause transition, with the goal of identifying intervention targets.
Eligible applicants include domestic and foreign nonprofits (501(c)(3) and non-501(c)(3)), higher education institutions (public and private), small businesses, for-profit organizations, state and local governments, tribal governments (federally and non-federally recognized), independent school districts, public or Indian housing authorities, faith-based or community-based organizations, Alaska Native and Native Hawaiian Serving Institutions, HBCUs, Hispanic-serving institutions, AANAPISIs, and TCCUs. No cost share is mentioned.
Research priorities encompass classic depressive symptoms co-occurring with menopause symptoms (hot flashes, night sweats, sleep disturbance), the role of reproductive steroids in mood and behavior regulation, diagnosis of mood and psychosis at specific menopausal stages, investigation of co-occurring psychiatric and menopause symptoms, psychosocial factors in midlife, and differential diagnoses. The program encourages interdisciplinary collaboration.
Peer review focuses on comprehensiveness of neurobiological and mechanistic understanding underlying mood and psychosis symptoms and hypothesis-driven design. The opportunity is assigned to the NIH Office of Research on Women's Health (CFDA 93.313) and the National Institute of Mental Health (CFDA 93.242). Award ceilings, award floors, number of anticipated awards, period of performance, and place of performance are not specified in the source materials.
Synopsis
The purpose of this Notice of Funding Opportunity (NOFO) is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Files
| File | Type | Posted |
|---|---|---|
| PAR-25-282-Full-Announcement.html | HTML file | |
| PKG00288959.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity